Europe approves Lilly's diabetes drug
26 November 2014 | News | By BioSpectrum Bureau
Europe approves Lilly's diabetes drug
The marketing authorisation is based primarily on six large Phase III trials
Eli Lily has announced that the European Commission (EU) has granted marketing approval to its injectable once-weekly Trulicity treatment for adults with type 2 diabetes.
Trulicity is a GLP-1 receptor agonists. The marketing authorisation is based primarily on six large Phase III trials and in the first five, Trulicity 1.5mg was superior to placebo and four commonly used type 2 diabetes medicines in reducing average blood sugar levels.
The drug can be taken any time of a day, with or without meals, and either by itself or with other treatments for the most common form of diabetes.
